An observational study in Rheumatic Heart Disease and Anticoagulant Adverse Reaction, sponsored by Helse Nord-Trøndelag HF. Recruiting at 4 sites in 2 countries. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.
Sponsored by Helse Nord-Trøndelag HF · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this bi-directional program of education, training and research activities based on sustainable development goals aim is to develop cardiac surgery service in Ethiopia.
The aim is to evaluate the short and long-term outcome of cardiac surgery for rheumatic heart disease in a low-income country compared to individuals not offered cardiac surgery due to limited availability of the service. Second aim is to evaluate the quality of anticoagulant therapy in patients after cardiac surgery for rheumatic heart disease in a low-income country .
Our objectives are:
Population: Approximately 50 RHD patients operated by Our team at Addis Abeba University Hospital, Ethiopia.
Follow up for 180-days for objective 1 and continous follow-up for objective 2. Comparison With matched Controls. Outcome measures: Mortality, complications (heart failure, arrhythmias, thrombosis, bleedings, stroke, infections)
62 studies on the registry are indexed under Rheumatic Heart Disease; 26 are open to participants now.
This study's planned enrollment of 200 is below the median of 1,423 across 23 observational studies indexed under Rheumatic Heart Disease.
Browse Rheumatic Heart Disease studies →Helse Nord-Trøndelag HF is the lead sponsor of 27 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Cases: Patients offered Cardiac surgery due to indication symptomatic rheumatic heart disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RHD patients undergoing Cardiac surgery at Addis Abeba University Hospital
Procedure: Cardiac surgery
RHD patients not offered Cardiac surgery
Norwegian patients on anticoagulant therapy due to mechanical valve implants
Short term outcome
Freedom from Death or complication
Time frame: 180 days
Time in therapeutic INR
Time in therapeutic window (anticoagulation)
Time frame: 2 years
Mitral valve area by Doppler
Influence of concomitant pathology for Echocardiographic assessment of mitral stenosis
Time frame: 14 days
Mitral phenotype in rheumatic heart disease
Influence of mitral valve phenotype with cardiac morphology and complications in untreated rheumatic heart disease patients
Time frame: 0 days
Plan to share: Undecided — No written plan. Under discussion.
Started Mar 2016 (actual). Primary completion is estimated for Dec 2025, 117 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helse Nord-Trøndelag HF